Studieoverzicht
Study name: DR22LOXO: An open-label, Multicenter study of LOXO-435 (LY3866288) in Advanced Solid Tumor Malignancies with FGFR3 Alterations
Histology | NSCLC, Other | ||
---|---|---|---|
Tumor stage | Stage III - IV | ||
Host / recruiting site 1 | Erasmus MC | Enrollment | On hold |
Therapy line | Later line (≥2L) | ||
Design |
This is a Phase 1a/b, open-label, multicenter study of LOXO-435 in participants with FGFR3-altered advanced solid tumors, including advanced or metastatic urothelial cancer (UC). |
||
Intervention | LOXO-435 is a potent, isoform-selective inhibitor of FGFR3 that is being developed to treat advanced solid tumors with activating gene alterations in FGFR3. |
||
Key outcome parameters | Safety and dose finding of LOXO-435 |
||
Key inclusion criteria |
|
||
Key exclusion criteria | -There is no restriction on number of prior therapies. |
||
Contact information | Log in voor de contactinformatie |